Precision BioSciences, Inc. Common Stock
DTIL Real Time Price USDRecent trades of DTIL by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by DTIL's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
Estimated quarterly lobbying spending
DTIL Revenue by Segment or Geography
New patents grants
-
Patent Title: Polynucleotides encoding engineered meganucleases having specificity for recognition sequences in the dystrophin gene Jun. 11, 2024
-
Patent Title: Polynucleotides encoding engineered meganucleases having specificity for recognition sequences in the dystrophin gene May. 28, 2024
-
Patent Title: Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir) Dec. 26, 2023
-
Patent Title: Polynucleotides encoding optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome Oct. 17, 2023
-
Patent Title: Optimized engineered nucleases having specificity for the human t cell receptor alpha constant region gene Oct. 17, 2023
-
Patent Title: Polynucleotides encoding engineered meganucleases having specificity for recognition sequences in the dystrophin gene Sep. 12, 2023
-
Patent Title: Engineered meganucleases specific for recognition sequences in the pcsk9 gene Jun. 20, 2023
-
Patent Title: Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir) Sep. 27, 2022
-
Patent Title: Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir) Jul. 12, 2022
-
Patent Title: Co-stimulatory domains for use in genetically-modified cells Mar. 29, 2022
-
Patent Title: Engineered nucleases useful for treatment of hemophilia a Mar. 22, 2022
-
Patent Title: Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome Mar. 15, 2022
-
Patent Title: Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene Mar. 08, 2022
-
Patent Title: Nucleic acids encoding engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene Mar. 08, 2022
-
Patent Title: Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir) Nov. 30, 2021
-
Patent Title: Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome Oct. 12, 2021
-
Patent Title: Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene Jul. 06, 2021
-
Patent Title: Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir) May. 18, 2021
-
Patent Title: Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome Dec. 01, 2020
-
Patent Title: Co-stimulatory domains for use in genetically-modified cells Oct. 13, 2020
-
Patent Title: Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene Oct. 13, 2020
-
Patent Title: Treatment of retinitis pigmentosa using engineered meganucleases Sep. 01, 2020
-
Patent Title: Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof Aug. 18, 2020
-
Patent Title: Self-limiting viral vectors encoding nucleases May. 26, 2020
-
Patent Title: Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome May. 26, 2020
-
Patent Title: Recognition sequences for i-crei-derived meganucleases and uses thereof May. 14, 2019
-
Patent Title: Recognition sequences for i-crei-derived meganucleases and uses thereof Apr. 30, 2019
-
Patent Title: Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene Oct. 09, 2018
-
Patent Title: Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene Oct. 09, 2018
-
Patent Title: Rationally-designed single-chain meganucleases with non-palindromic recognition sequences Aug. 07, 2018
-
Patent Title: Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene Jun. 12, 2018
-
Patent Title: Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene Jun. 12, 2018
-
Patent Title: Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene May. 15, 2018
-
Patent Title: Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene Apr. 24, 2018
-
Patent Title: Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene Apr. 24, 2018
-
Patent Title: Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene Feb. 13, 2018
-
Patent Title: Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene Feb. 13, 2018
-
Patent Title: Methods and products for producing engineered mammalian cell lines with amplified transgenes Nov. 21, 2017
-
Patent Title: Recognition sequences for i-crei-derived meganucleases and uses thereof Jun. 20, 2017
-
Patent Title: Rationally-designed single-chain meganucleases with non-palindromic recognition sequences Sep. 06, 2016
-
Patent Title: Rationally-designed single-chain meganucleases with non-palindromic recognition sequences May. 17, 2016
-
Patent Title: Rationally-designed single-chain meganucleases with non-palindromic recognition sequences May. 21, 2013
-
Patent Title: Rationally-designed meganuclease variants of lig-34 and i-crei for maize genome engineering Dec. 25, 2012
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to DTIL
Recent picks made for DTIL stock on CNBC
ETFs with the largest estimated holdings in DTIL
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $DTIL stock a Buy, Sell, or Hold?
- What is the price target for $DTIL stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $DTIL stock?
- Who owns the most shares of $DTIL stock?
- What funds own $DTIL stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view DTIL Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.